Rich Pharmaceuticals competitors

Rich Pharmaceuticals's competitors include Syndax Pharmaceuticals, G1 Therapeutics, Rexahn Pharmaceuticals and Alpine Immune Sciences
Add company...
Rich Pharmaceuticals
Rich Pharmaceuticals is a biopharmaceutical company that is focused on the development of its lead product, RP-323, for the treatment of acute myelogenous leukemia in refractory patients.
Syndax Pharmaceuticals
Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy.
G1 Therapeutics
G1 is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer.
Rexahn Pharmaceuticals
Rexahn Pharmaceuticals develops treatments for cancer, central nervous system disorders, and other unmet medical needs in the United States.
Alpine Immune Sciences
Modern therapies targeting the immune synapse.
Founding Date
Founding Date
N/A
Founding Date
2005
Founding Date
2008
Founding Date
2001
Founding Date
2015
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Private
Tags
Locations
Locations
Beverly Hills, US HQ
Locations
Waltham, US HQ
Locations
Durham, US HQ
Locations
Rockville, US HQ
Locations
Seattle, US HQ
Employees
Employees
1
Employees
3237% decrease
Employees
3827% increase
Employees
20
Employees
N/A
Valuation ($)
Valuation ($)
206.6 k
Valuation ($)
171.4 m
Valuation ($)
1.9 b
Valuation ($)
50.5 m
Valuation ($)
N/A
Twitter followers
Twitter followers
N/A
Twitter followers
108
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
166

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$2.1m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
N/A
Revenue (est.)
$1.7m (FY, 2017)
Net income
Net income
N/A
Net income
($60.8m) (FY, 2017)
Net income
($60.1m) (FY, 2017)
Net income
($25.3m) (FY, 2017)
Net income
($7.8m) (FY, 2017)

Funding

Total funding raised
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 92.5m
Total funding raised
$ 5m
Total funding raised
$ 49.3m
For sources of this data, please see the company profileDownload Excel

View company profiles

Syndax Pharmaceuticals
HQ
Waltham, US
Employees
32↓ 37% decrease

Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy.

View company
G1 Therapeutics
HQ
Durham, US
Employees
38↑ 27% increase

G1 is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of cancer.

View company
Rexahn Pharmaceuticals
HQ
Rockville, US
Employees
20

Rexahn Pharmaceuticals develops treatments for cancer, central nervous system disorders, and other unmet medical needs in the United States.

View company
Alpine Immune Sciences
HQ
Seattle, US

Modern therapies targeting the immune synapse.

View company